Clinical Trial Update: The GRK2 Inhibitor Paroxetine as a Novel Adjunct to Conventional Therapy in Rheumatoid Arthritis Patients [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating paroxetine as a GRK2 inhibitor adjunct to conventional therapy for rheumatoid arthritis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Paroxetine (Paroxetine hydrochloride)

Snippet

Sponsor: Sadat City University | Conditions: Rheumatoid Arthritis | Phase 1, Phase 2 | Status: WITHDRAWN